Alta Capital Management buys $32,999,797 stake in Celgene Corporation (CELG)

Celgene Corporation (CELG) : Alta Capital Management scooped up 100,334 additional shares in Celgene Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 13, 2016. The investment management firm now holds a total of 327,932 shares of Celgene Corporation which is valued at $32,999,797.Celgene Corporation makes up approximately 2.09% of Alta Capital Management’s portfolio.

Other Hedge Funds, Including , Private Bank Trust Co reduced its stake in CELG by selling 95 shares or 4.13% in the most recent quarter. The Hedge Fund company now holds 2,207 shares of CELG which is valued at $222,090. Celgene Corporation makes up approx 0.03% of Private Bank Trust Co’s portfolio.Daiwa Sb Investments Ltd. reduced its stake in CELG by selling 4,520 shares or 30.52% in the most recent quarter. The Hedge Fund company now holds 10,290 shares of CELG which is valued at $1,045,876. Celgene Corporation makes up approx 0.27% of Daiwa Sb Investments Ltd.’s portfolio. Lgt Capital Partners Ltd. added CELG to its portfolio by purchasing 66,340 company shares during the most recent quarter which is valued at $6,917,272. Celgene Corporation makes up approx 0.97% of Lgt Capital Partners Ltd.’s portfolio.Bristol John W Co Inc Ny boosted its stake in CELG in the latest quarter, The investment management firm added 118,501 additional shares and now holds a total of 648,217 shares of Celgene Corporation which is valued at $67,589,587. Celgene Corporation makes up approx 1.85% of Bristol John W Co Inc Ny’s portfolio.

Celgene Corporation closed down -2.63 points or -2.52% at $101.64 with 34,28,438 shares getting traded on Tuesday. Post opening the session at $103.6, the shares hit an intraday low of $101.021 and an intraday high of $103.881 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Celgene Corporation reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $1.39. The company had revenue of $2754.00 million for the quarter, compared to analysts expectations of $2709.02 million. The company’s revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS.

Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.

Leave a Reply

Celgene Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Celgene Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.